WHO Model Prescribing Information: Drugs Used in Skin Diseases
(1997; 132 pages) [French] [Spanish] Ver el documento en el formato PDF
Índice de contenido
Ver el documentoPreface
Ver el documentoIntroduction
Abrir esta carpeta y ver su contenidoParasitic infections
Cerrar esta carpetaInsect and arachnid bites and stings
Ver el documentoMosquitos and other biting flies
Ver el documentoBees, wasps, hornets and ants
Ver el documentoBedbugs and reduviid bugs
Ver el documentoScorpions
Ver el documentoPoisonous spiders
Ver el documentoChiggers or harvest mites
Ver el documentoTicks
Abrir esta carpeta y ver su contenidoSuperficial fungal infections
Abrir esta carpeta y ver su contenidoSubcutaneous fungal infections
Abrir esta carpeta y ver su contenidoBacterial infections
Abrir esta carpeta y ver su contenidoViral infections
Abrir esta carpeta y ver su contenidoEczematous diseases
Abrir esta carpeta y ver su contenidoScaling diseases
Abrir esta carpeta y ver su contenidoPapulosquamous diseases
Ver el documentoCutaneous reactions to drugs
Abrir esta carpeta y ver su contenidoPigmentary disorders
Abrir esta carpeta y ver su contenidoPremalignant lesions and malignant tumours
Abrir esta carpeta y ver su contenidoPhotodermatoses
Abrir esta carpeta y ver su contenidoBullous dermatoses
Ver el documentoAlopecia areata
Ver el documentoUrticaria
Abrir esta carpeta y ver su contenidoConditions common in children
Ver el documentoAcne vulgaris
Ver el documentoPruritus
Ver el documentoTropical ulcers
Abrir esta carpeta y ver su contenidoAntimicrobial drugs
Abrir esta carpeta y ver su contenidoAntifugal drugs
Abrir esta carpeta y ver su contenidoAntiseptic agents
Abrir esta carpeta y ver su contenidoKeratoplastic and keratolytic agents
Abrir esta carpeta y ver su contenidoScabicides and pediculicides
Abrir esta carpeta y ver su contenidoAnti-inflammatory and antipruritic drugs1
Abrir esta carpeta y ver su contenidoAntiallergics and drugs used in anaphylaxis
Abrir esta carpeta y ver su contenidoUltraviolet radiation-blocking agents (sunscreens)
Abrir esta carpeta y ver su contenidoMiscellaneous drugs
Abrir esta carpeta y ver su contenidoAnnex
Ver el documentoSelected WHO Publications of Related Interest
Ver el documentoBack cover
 

Bees, wasps, hornets and ants

Bees, wasps, hornets and ants are species of Hymenoptera. Their stings often cause intense and painful local reactions. In previously sensitized persons there is an associated danger of anaphylaxis, which can range in severity from mild pruritus and urticaria to potentially fatal shock characterized by severe hypotension associated with loss of fluid from the intravascular compartment, bronchoconstriction and laryngeal angio-oedema.

Management

When the sting remains implanted in the skin, it should be carefully removed with a needle or knife-blade. Topical administration of calamine lotion may be of symptomatic value. Cooling of the affected area provides some relief when local reactions are severe. Systemic antihistamines and analgesics can be given to relieve pruritus or pain. Topical antihistamines have no proven value. Systemic corticosteroids may be appropriate if there are severe side-effects. Patients who sustain multiple bee stings at the same time are particularly at risk for systemic reactions, and should be seen and kept under observation at a hospital or medical post, whenever possible.

Any person who collapses, or who complains of wheezing, a feeling of anxiety or faintness, generalized itching, or tightness in the chest within approximately 1 hour of being stung by an insect should be treated as having anaphylactic shock. All such patients should receive an immediate intramuscular injection of 0.5-1.0 ml of epinephrine, 1:1000 solution. This promotes bronchodilatation and vasoconstriction and has a stimulant effect on the heart. It may also reduce the release of histamine and other vasoactive substances into the circulation by stabilizing the outer membrane of mast cells. Cardiac dysrhythmias and hypertension are likely to occur if over 2 ml of epinephrine is given within 5 minutes. When the response to epinephrine is transient, use of a plasma expander should be considered. Intravenous corticosteroids should not be administered initially, but may be used after the patient has received epinephrine for initial stabilization. There is no convincing evidence that antihistamines are of therapeutic value in established anaphylactic shock. Basic cardiopulmonary resuscitation should be started in the event of pulmonary or cardiac arrest.

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 19 enero 2012